Código QR (código de barras bidimensional)

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports

BackgroundPatients with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) have poor prognosis. Trastuzumab deruxtecan (T-DXd) is the first targeted therapy approved for the treatment of patients with HER2-mutant metastatic NSCLC, but the evidence in those with...

ver descrição completa

Na minha lista:
Principais autores: Yan Meng, Yanping Du, Xiaolin Liu, Jue Huang, Hanhan Chen, Chunxia He
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2025-08-01
coleção:Frontiers in Immunology
Assuntos:
trastuzumab deruxtecan
non-small cell lung cancer
human epidermal growth factor receptor 2
mutation
case series
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1631768/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados